Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mouse-human IgG1/kappa antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases. Unfortunately, response failure and side-effects due to immunogenicity of the drug are not rare. In this study, we have compared different methods of assessing drug levels and anti-infliximab antibodies (Abs) and analysed the character of these Abs in sera of RA patients treated with infliximab for 1.5-18 months. METHODS: Functional serum infliximab levels and anti-infliximab Abs were measured by fluid-phase RIAs using 125I-labelled ligands in combination with molecular size and affinity chromatography, and immune complex precipitation. RESULTS: Anti-infliximab Abs were predominantly IgG, 36% being IgG4, and half the immune complexes were lambda-light-chain-positive. Ab titres were associated with inhibition of TNF binding to the drug, and low trough levels of infliximab were most frequent in anti-infliximab Ab-positive sera. Cross-binding to two other anti-TNF drugs was not observed. Detection of anti-infliximab Abs by solid-phase RIA using cross-binding of plastic-fixed and soluble infliximab exhibited low sensitivity and the data were inconsistent with results obtained from binding of the Abs to soluble infliximab. CONCLUSIONS: Specific and neutralizing anti-infliximab antibodies develop in RA patients treated with infliximab, and that low trough levels of functional infliximab are associated with the presence of such antibodies. The most sensitive antibody assay involved binding to soluble and intact infliximab. Assessments of bioavailability and immunogenicity of anti-TNF biologicals may be used to optimize dose regimens and prevent prolonged use of inadequate therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported to occur with drugs such as salmeterol, 51 alpha agonists including apraclonidine and brimonidine, 52 and infliximab.53”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [53]
Citations
Cites
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Farrell, R. J., Alsahli, M., Jeen, Y.-T., Falchuk, K. R., Peppercorn, M. A., & Michetti, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50145 · Cited by 550
Molecular Basis of Fc Receptor Function
Hulett, M. D., & Hogarth, P. M. (1994) · Advances in Immunology · doi:10.1016/s0065-2776(08)60671-9 · Cited by 505
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 384
Self-citationSandborn, W. J., Hanauer, S., Loftus, E. V., Tremaine, W. J., Kane, S., Cohen, R., Hanson, K., Johnson, T., Schmitt, D., & Jeche, R. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40462.x · Cited by 276
Geborek, P., Crnkic, M., Petersson, I. F., & Saxne, T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.9.793 · Cited by 253
Self-citationAnti-Tumor Necrosis Factor-α Therapy of Rheumatoid Arthritis
Feldmann, M., Elliott, M. J., Maini, R. N., & Woody, J. N. (1997) · Advances in Immunology · doi:10.1016/s0065-2776(08)60891-3 · Cited by 230
van Vollenhoven, R., Harju, A., Brannemark, S., & Klareskog, L. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009589 · Cited by 221
Wolbink, G. J., Voskuyl, A. E., Lems, W. F., de Groot, E., Nurmohamed, M. T., Tak, P. P., Dijkmans, B. A. C., & Aarden, L. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030452 · Cited by 215
Cited by
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Afif, W., Loftus, E. V., Faubion, W. A., Kane, S. V., Bruining, D. H., Hanson, K. A., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.9 · Cited by 486
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
Metadata
- Authors
- Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K.
- Affiliations
- Rigshospitalet (DK)
- Lund University (SE)
- ORCID
- Geborek, P.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-08-05
- Volume
- 46
- Issue
- 12
- Pages
- 1828-1834
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2122735365
- Cited by
- 189
- References
- 29
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 8 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 18 · 2014: 22 · 2013: 16 · 2012: 25
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- infliximab, anti-infliximab antibodies, drug immunogenicity, rheumatoid arthritis, drug monitoring, trough concentration, neutralizing antibodies, IgG4, lambda light chain, immune complexes, solid-phase radioimmunoassay, bioavailability, dose optimization
- MeSH terms
- Infliximab, Adult, Aged, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Arthritis, Rheumatoid, Biological Availability, Dose-Response Relationship, Drug, Drug Administration Schedule, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Male, Middle Aged, Monitoring, Physiologic, Radioimmunoassay, Sensitivity and Specificity, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. https://app.cochat.ai/papers/10.1093/rheumatology/kem261
- The paper
- Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007). Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. https://doi.org/10.1093/rheumatology/kem261
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.